Form 4: Pfizer Director James Quincey Reports Acquisition of Phantom Stock Units

Director James Quincey reports acquiring phantom stock units representing deferred director's compensation in Pfizer Inc.

Summary

• On March 28, 2024, James Quincey, a director of Pfizer Inc., acquired 1,396.396 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The price of the underlying common stock was $27.75.
• Following the transaction, Quincey directly owns 40,379.982 shares.
• The filing was signed on April 01, 2024, by Susan E. Grant under power of attorney for James Quincey.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a standard transaction related to director compensation.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of phantom stock units aligns the director's interests with those of the shareholders.

Key Dates